MDS Invests in Cellular Screening Instrumentation
The acquisition fills in MDS’s product line by providing an ultra high-throughput system for analyzing the entire microplate well, in contrast to microplate readers and confocal microscopy-based systems that examine a portion of the well. The IsoCyte also provides more efficient analyses of live-cell protein-protein interactions using of FRET assays.
Sunnyvale, CA 6/27/08—MDS Analytical Technologies has acquired Blueshift Biotechnologies for $13 million. Located in Sunnyvale, California, Blueshift Biotechnologies is the maker of the IsoCyte benchtop laser-scanning cytometer for cellular screening. “This acquisition fills a gap in our current product portfolio, allowing us to offer our pharmaceutical research customers fast and simple cellular analysis with a line of instrumentation that images the whole well at true high-throughput screening rates,” stated MDS Analytical Technologies President Andy Boorn. “There are currently 14 IsoCyte instruments installed at academic, biotech and pharmaceutical companies in North America. With our extensive global sales force, we have the ability to bring this novel product to a wider global market.”
